ClinicalTrials.gg
CompletedNCT03843060Updated Apr 22, 2019

A Phase 1 Study to Assess the Pharmacokinetics of AZD9977 Administered Alone and in Combination With Itraconazole in Healthy Volunteers

A Phase 1 interventional study of AZD9977 and Itraconazole in Heart Failure With Preserved Ejection Fraction (HFpEF), sponsored by AstraZeneca. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-04-22.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Apr 2019, 7 years 7 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
14
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 64 studies in Heart Failure by AstraZeneca — 6 open to participants now, 8 under way, 3 of them phase 3. Heart Failure · AstraZeneca.

Enrollment
33rd of 39
14 · median 160
Started
2019
with 5 others
Phase 1
13 of 64
none open now
Registered
28th of 64
by date

Among the 64 studies in Heart Failure by AstraZeneca, this one is the 33rd largest by enrollment of the 39 interventional ones that give a count, is one of 6 that started in 2019, is one of 13 in phase 1, and was the 28th registered.

Heart Failure

6,334 studies on the registry are indexed under Heart Failure; 1,394 are open to participants now.

Browse Heart Failure studies →

Open to participants now

6 of the 64 studies in Heart Failure by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 967 Heart Failure studies recruiting now, 690 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies in Heart Failure by AstraZeneca, or all of them as a file.
02

Study summary

This is an open-label, non-randomized, fixed sequence study conducted at a single study center with primary aim to assess the pharmacokinetics (PK) of AZD9977 in healthy volunteers when administered alone and in combination with multiple doses of itraconazole.

Read the detailed description

This is an open-label, non-randomized, fixed sequence study conducted at a single study center with primary aim to assess the pharmacokinetics (PK) of AZD9977 in healthy volunteers when administered alone and in combination with multiple doses of itraconazole. Two types of treatments (treatment period 1 and treatment period 2) will be administered in a fixed order separated by a washout period of 3 days or more. Treatment period 1 will be single dose of AZD9977 (Dose 1) administration, in the fed state, on Day 1 followed by at least 3 days washout period. For treatment period 2, Itraconazole will be administered daily (Dose 2) from Day 4 to Day 8 plus AZD9977 (Dose 1, fed state) will be administered as a single dose on Day 7. Dose of itraconazole has to be taken at -1 hour (1 hour prior to AZD9977 dosing) when co-administered with AZD9977.

03

Conditions studied

  • Heart Failure With Preserved Ejection Fraction (HFpEF)

Browse trials for

Keywords

  • Congestive heart failure
  • Healthy volunteers
  • Itraconazole
  • Drug-drug interaction
  • Pharmacokinetics
  • Open-label non-randomized
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provision of signed and dated, written prior to any study specific procedures.
  2. Healthy male and female participants of non- aged 18 - 55 years with suitable veins for cannulation or repeated venipuncture.
  3. Females must have a negative pregnancy test at screening and on admission to the unit, must not be lactating and must be of non-childbearing potential, confirmed at screening by fulfilling one of the following criteria:

    1. defined as amenorrhea for at least 12 months or more following cessation of all exogenous hormonal treatments and follicle stimulating hormone (FSH) levels ≥40 mlU/ml.
    2. Documentation of irreversible surgical sterilization by hysterectomy, bilateral oophorectomy or bilateral salpingectomy but not tubal ligation.
  4. Have a (BMI) between 18 and 30 kg/m2 inclusive and weigh at least 50 kg and no more than 100 kg inclusive.

Exclusion criteria

Exclusion Criteria:

  1. History of any disease or disorder which, in the opinion of the PI, may either put the volunteer at risk because of participation in the study, or influence the results or the volunteer's ability to participate in the study..
  2. History or presence of gastrointestinal, hepatic or renal disease, or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.
  3. Any clinically significant illness, medical/surgical procedure, or trauma within 4 weeks of the first administration of IMP.

Any clinically significant abnormalities in clinical chemistry, hematology, or urinalysis results, as judged by the PI including serum potassium > 5.0 mmol/L, serum hsTnI > 25.6 pg/mL, and NT-pro-BNP > 124 pg/mL.

  1. Any clinically significant abnormal findings in vital signs as specified below and as judged by the PI at screening and on admission including:
  1. Systolic blood pressure (SBP) \< 90 mmHg or > 140 mmHg.
  2. Diastolic blood pressure (DBP) \< 50 mmHg or > 90 mmHg.
  3. HR \< 45 or > 90 beats per minute (bpm). 6. Any clinically significant abnormalities on 12-lead , as judged by the PI.

    1. Any positive result on screening for serum surface antigen, antibody, and (HIV) antibody.
    1. Known or suspected history of drug abuse in the last 12 months as judged by the Investigator.
    1. Has received another new chemical entity (defined as a compound which has not been approved for marketing) within 3 months of the first administration of IMP in this study. The period of exclusion begins 3 months after the final dose or 1 month after the last visit whichever is the longest.
    1. Plasma donation within 1 month of screening or any blood donation/loss more than 500 mL during the 3 months prior to screening.
    1. History of severe allergy/ or ongoing allergy/hypersensitivity, as judged by the PI or history of hypersensitivity to drugs with a similar chemical structure or class to AZD9977.
    1. Current smokers or those who have smoked or used nicotine products (including e cigarettes) within the 3 months prior to screening.
    1. Positive screen for drugs of abuse, cotinine or alcohol at screening or on each admission to the study center.
    1. Use of drugs with enzyme-inducing properties such as St John's Wort within 3 weeks prior to the first administration of IMP.
    1. Use of any prescribed or non prescribed medication including antacids, analgesics (other than paracetamol/acetaminophen), herbal remedies, megadose vitamins (intake of 20 to 600 times the recommended daily dose) and minerals during the 2 weeks prior to the first administration of IMP or longer if the medication has a long half life.
    1. Known or suspected history of alcohol or drug abuse or excessive intake of alcohol in the last 12 months as judged by the PI.
    1. Involvement of any AstraZeneca, PAREXEL or study site employee or their close relatives.
    1. Participants who have previously received AZD9977. 19. Judgment by the PI that the participant should not participate in the study if they have any ongoing or recent (i.e., during the screening period) minor medical complaints that may interfere with the interpretation of study data or are considered unlikely to comply with study procedures, restrictions, and requirements.
    1. Vulnerable participants , e.g., kept in detention, protected adults under guardianship, trusteeship, or committed to an institution by governmental or juridical order.
    1. Participants with any special dietary restrictions such as participants that are lactose intolerant or are vegetarians/vegans.
    1. Drugs affecting (itraconazole) should be refrained from use for 3 weeks prior to study commencement and thereafter until study completion.
    1. The following exclusion criterion is driven by from the proposed concomitant CYP3A4 (itraconazole) inhibitor medications: Itraconazole (Sporanox) capsules are contra-indicated in patients with known hypersensitivity to itraconazole or to any of the .
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
14 participants (actual)

Study arms

  • Experimental
    Single AZD9977

    During this treatment period, healthy participants will be administered with a single AZD9977 (Dose 1) dose, in the fed state, on Day 1 followed by at least 3 days washout period.

    Drug: AZD9977

  • Experimental
    Itraconazole + AZD9977

    During this treatment period, healthy participants will be administered with Itraconazole (Dose 2) from Day 4 to Day 8 plus will be administrated with AZD9977 (Dose 1, fed state) as a single dose on Day 7. Dose of itraconazole will be taken at -1 hour (1 hour prior to AZD9977 dosing) when co-administered with AZD9977.

    Drug: Itraconazole

Interventions

  • Participants will receive single AZD9977 (Dose 1) capsule orally once daily in fed state, on Day 1 followed by at least 3 days washout period.

  • Participants will receive Itraconazole daily (Dose 2) capsule orally once daily from Day 4 to Day 8 plus will be administered AZD9977 (Dose 1, fed state) as a single dose on Day 7. Dose of itraconazole has to be taken at -1 hour (1 hour prior to AZD9977 dosing) when co-administered with AZD9977.

    Also known as: Sporanox

06

What researchers measure

Primary outcomes

  1. Area under plasma concentration-time curve from time zero to infinity (AUC) for AZD9977

    To access pharmacokinetics (PK) of AZD9977 in healthy volunteers when administered alone and in combination with multiple doses of itraconazole

    Time frame: Day 1 to 3: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 12, 16, 24, 36 and 48 hours post-dose. Day 4 to 9: pre-dose on Day 7 and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 12, 16, 24, 36 and 48 hours post-dose

  2. Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration (AUClast) for AZD9977

    To access pharmacokinetics (PK) of AZD9977 in healthy volunteers when administered alone and in combination with multiple doses of itraconazole

    Time frame: Day 1 to 3: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 12, 16, 24, 36 and 48 hours post-dose. Day 4 to 9: pre-dose on Day 7 and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 12, 16, 24, 36 and 48 hours post-dose

  3. Maximum observed plasma concentration (Cmax) for AZD9977

    To access pharmacokinetics (PK) of AZD9977 in healthy volunteers when administered alone and in combination with multiple doses of itraconazole

    Time frame: Day 1 to 3: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 12, 16, 24, 36 and 48 hours post-dose. Day 4 to 9: pre-dose on Day 7 and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 12, 16, 24, 36 and 48 hours post-dose

Secondary outcomes

  1. Time to reach Maximum Observed Plasma Concentration (tMax)

    To access pharmacokinetics (PK) of AZD9977 in healthy volunteers when administered alone and in combination with multiple doses of itraconazole

    Time frame: Day 1 to 3: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 12, 16, 24, 36 and 48 hours post-dose. Day 4 to 9: pre-dose on Day 7 and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 12, 16, 24, 36 and 48 hours post-dose

  2. Half-life associated with terminal slope (λz) of a semi-logarithmic concentration-time curve (t½λz)

    To access pharmacokinetics (PK) of AZD9977 in healthy volunteers when administered alone and in combination with multiple doses of itraconazole

    Time frame: Day 1 to 3: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 12, 16, 24, 36 and 48 hours post-dose. Day 4 to 9: pre-dose on Day 7 and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 12, 16, 24, 36 and 48 hours post-dose

  3. Mean residence time of the unchanged drug in the systemic circulation from time zero to infinity (MRT)

    To access pharmacokinetics (PK) of AZD9977 in healthy volunteers when administered alone and in combination with multiple doses of itraconazole.

    Time frame: Day 1 to 3: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 12, 16, 24, 36 and 48 hours post-dose. Day 4 to 9: pre-dose on Day 7 and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 12, 16, 24, 36 and 48 hours post-dose

  4. Terminal elimination rate constant (λz)

    To access pharmacokinetics (PK) of AZD9977 in healthy volunteers when administered alone and in combination with multiple doses of itraconazole

    Time frame: Day 1 to 3: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 12, 16, 24, 36 and 48 hours post-dose. Day 4 to 9: pre-dose on Day 7 and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 12, 16, 24, 36 and 48 hours post-dose

  5. Apparent total body clearance of drug from plasmsa after extravascular administration (CL/F)

    To access pharmacokinetics (PK) of AZD9977 in healthy volunteers when administered alone and in combination with multiple doses of itraconazole

    Time frame: Day 1 to 3: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 12, 16, 24, 36 and 48 hours post-dose. Day 4 to 9: pre-dose on Day 7 and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 12, 16, 24, 36 and 48 hours post-dose

  6. Apparent volume of distribution during the terminal phase after extravascular administration (Vz/F)

    To access pharmacokinetics (PK) of AZD9977 in healthy volunteers when administered alone and in combination with multiple doses of itraconazole

    Time frame: Day 1 to 3: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 12, 16, 24, 36 and 48 hours post-dose. Day 4 to 9: pre-dose on Day 7 and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 12, 16, 24, 36 and 48 hours post-dose

  7. Number of participants with adverse events (AEs)

    To assess AEs as variable of safety and tolerability after administration of single dose of AZD9977 in combination with itraconazole.

    Time frame: From screening (Day -28) till follow-up visit (up to approximately 6 weeks)

  8. Number of participants with abnormal blood pressure (both systolic and diastolic blood pressure)

    To measure BP as variable of safety and tolerability after administration of single dose of AZD9977 in combination with itraconazole. BP will be collected after the participants has rested in the supine position for at least 5 minutes.

    Time frame: From screening (Day -28) till follow-up visit (up to approximately 6 weeks)

  9. Number of participants with abnormal pulse rate

    To measure pulse rate as variable of safety and tolerability after administration of single dose of AZD9977 in combination with itraconazole. Pulse rate will be collected after the participants has rested in the supine position for at least 5 minutes.

    Time frame: From screening (Day -28) till follow-up visit (up to approximately 6 weeks)

  10. Number of participants with abnormal 12-lead Electrocardiograms (ECG)

    To examine the safety and tolerability of AZD9977 in combination with itraconazole. 12-lead safety ECG will be obtained after the participant rested in the supine position for at least 10 minutes using the sites own ECG machines. The Principal Investigator (PI) will judge the overall interpretation as normal or abnormal and this evaluation will be reported in ClinBase. If abnormal, it will be further documented as to whether or not the abnormality is clinically significant by the PI.

    Time frame: From screening (Day -28) till follow-up visit (up to approximately 6 weeks)

  11. Number of participants with abnormal physical examination findings

    To assess any clinically significant abnormal physical examination findings as a variable of safety and tolerability after administration of single dose of AZD9977 in combination with itraconazole. The complete physical examinations will include an assessment of the general appearance, respiratory, cardiovascular, abdomen, skin, head, and neck (including ears, eyes, nose, and throat), lymph nodes, thyroid, musculoskeletal and neurological systems. The brief physical examinations will include an assessment of the general appearance, skin, abdomen, cardiovascular system and respiratory.

    Time frame: From screening (Day -28) till follow-up visit (up to approximately 6 weeks)

  12. Number of participants with abnormal laboratory assessments: Hematology- White blood cell (WBC) count

    To assess the white blood cell count as variables of safety and tolerability after administration of single dose of AZD9977 in combination with itraconazole

    Time frame: From screening (Day -28) till follow-up visit (up to approximately 6 weeks)

  13. Number of participnats with abnormal laboratory assessments: Hematology- Red blood cell (RBC) count

    To assess the red blood cell count as variables of safety and tolerability after administration of single dose of AZD9977 in combination with itraconazole

    Time frame: From screening (Day -28) till follow-up visit (up to approximately 6 weeks)

  14. Number of paticipants with abnormal laboratory assessments: Hematology - Hemoglobin (Hb)

    To assess the Hb as variables of safety and tolerability after administration of single dose of AZD9977 in combination with itraconazole

    Time frame: From screening (Day -28) till follow-up visit (up to approximately 6 weeks)

  15. Number of participants with abnormal laboratory assessments: Hematology - Hematocrit (HCT) and Reticulocyte absolute count

    To assess the HCT and reticulocyte absolute count as variables of safety and tolerability after administration of single dose of AZD9977 in combination with itraconazole.

    Time frame: From screening (Day -28) till follow-up visit (up to approximately 6 weeks)

  16. Number of participants with abnormal laboratory assessments: Hematology - Mean corpuscular hemoglobin (MCH)

    To assess the MCH as variables of safety and tolerability after administration of single dose of AZD9977 in combination with itraconazole.

    Time frame: From screening (Day -28) till follow-up visit (up to approximately 6 weeks)

  17. Number of participants with abnormal laboratory assessments: Hematology - Mean corpuscular volume (MCV)

    To assess the MCV as variables of safety and tolerability after administration of single dose of AZD9977 in combination with itraconazole.

    Time frame: From screening (Day -28) till follow-up visit (up to approximately 6 weeks)

  18. Number of participants with abnormal laboratory assessments: Hematology - Mean corpuscular hemoglobin concentration (MCHC)

    To assess the MCHC as variables of safety and tolerability after administration of single dose of AZD9977 in combination with itraconazole.

    Time frame: From screening (Day -28) till follow-up visit (up to approximately 6 weeks)

  19. Number of participants with abnormal laboratory assessments: Hematology- Neutrophils absolute count

    To assess the neutrophils absolute count as variables of safety and tolerability after administration of single dose of AZD9977 in combination with itraconazole

    Time frame: From screening (Day -28) till follow-up visit (up to approximately 6 weeks)

  20. Number of participants with abnotmal laboratory assessments: Hematology- Lymphocytes absolute count

    To assess the Lymphocytes absolute count as variables of safety and tolerability after administration of single dose of AZD9977 in combination with itraconazole

    Time frame: From screening (Day -28) till follow-up visit (up to approximately 6 weeks)

  21. Number of participants with abnormal laboratory assessments: Hematology- Monocytes absolute count

    To assess the Monocytes absolute count as variables of safety and tolerability after administration of single dose of AZD9977 in combination with itraconazole

    Time frame: From screening (Day -28) till follow-up visit (up to approximately 6 weeks)

  22. Number of participants with abnormal laboratory assessments: Hematology- Eosinophils absolute count

    To assess the Eosinophils absolute count as variables of safety and tolerability after administration of single dose of AZD9977 in combination with itraconazole

    Time frame: From screening (Day -28) till follow-up visit (up to approximately 6 weeks)

  23. Number of participants with abnormal laboratory assessments: Hematology- Basophils absolute count

    To assess the Basophils absolute count as variables of safety and tolerability after administration of single dose of AZD9977 in combination with itraconazole

    Time frame: From screening (Day -28) till follow-up visit (up to approximately 6 weeks)

  24. Number of participants with abnormal laboratory assessments: Hematology- Platelets count

    To assess the Platelets count as variables of safety and tolerability after administration of single dose of AZD9977 in combination with itraconazole

    Time frame: From screening (Day -28) till follow-up visit (up to approximately 6 weeks)

  25. Number of participants with abnormal laboratory assessments: Serum Clinical chemistry - Calcium, potassium, phosphate and sodium

    To assess the serum calcium, potassium, phosphate and sodium level as variables of safety and tolerability after administration of single dose of AZD9977 in combination with itraconazole.

    Time frame: From screening (Day -28) till follow-up visit (up to approximately 6 weeks)

  26. Number of participants with abnormal laboratory assessments: Serum Clinical chemistry - Liver enzymes

    To assess the serum Alanine aminotransferase (ALT), Alkaline phosphatase (ALP), Aspartate aminotransferase (AST) and Gamma glutamyl transpeptidase (GGT) level as variables of safety and tolerability after administration of single dose of AZD9977 in combination with itraconazole.

    Time frame: From screening (Day -28) till follow-up visit (up to approximately 6 weeks)

  27. Number of participants with abnormal laboratory assessments: Serum Clinical chemistry - Albumin

    To assess the albumin level as variables of safety and tolerability after administration of single dose of AZD9977 in combination with itraconazole.

    Time frame: From screening (Day -28) till follow-up visit (up to approximately 6 weeks)

  28. Number of participants with abnormal laboratory assessments: Serum Clinical chemistry - C reactive protein (CRP)

    To assess the CRP level as variables of safety and tolerability after administration of single dose of AZD9977 in combination with itraconazol

    Time frame: From screening (Day -28) till follow-up visit (up to approximately 6 weeks)

  29. Number of participants with abnormal laboratory assessments: Serum Clinical chemistry - Creatine kinase (CK)

    To assess the CK level as variables of safety and tolerability after administration of single dose of AZD9977 in combination with itraconazole.

    Time frame: From screening (Day -28) till follow-up visit (up to approximately 6 weeks)

  30. Number of participants with abnormal laboratory assessments: Serum Clinical chemistry - Creatinine

    To assess the creatinine level as variables of safety and tolerability after administration of single dose of AZD9977 in combination with itraconazole.

    Time frame: From screening (Day -28) till follow-up visit (up to approximately 6 weeks)

  31. Number of participants with abnormal laboratory assessments: Serum Clinical chemistry - Glucose (fasting)

    To assess the fasting glucose level as variables of safety and tolerability after administration of single dose of AZD9977 in combination with itraconazole.

    Time frame: From screening (Day -28) till follow-up visit (up to approximately 6 weeks)

  32. Number of participants with abnormal laboratory assessments: Serum Clinical chemistry- Uric acid

    To assess the uric acid level as variables of safety and tolerability after administration of single dose of AZD9977 in combination with itraconazole.

    Time frame: From screening (Day -28) till follow-up visit (up to approximately 6 weeks)

  33. Number of participants with abnormal laboratory assessments: Serum Clinical chemistry- BUN

    To assess the BUN level as variables of safety and tolerability after administration of single dose of AZD9977 in combination with itraconazole.

    Time frame: From screening (Day -28) till follow-up visit (up to approximately 6 weeks)

  34. Number of participants with abnormal laboratory assessments: Serum Clinical chemistry - Total Bilirubin (TBL)

    To assess the TBL level as variables of safety and tolerability after administration of single dose of AZD9977 in combination with itraconazole.

    Time frame: From screening (Day -28) till follow-up visit (up to approximately 6 weeks)

  35. Number of participants with abnormal laboratory assessments: Serum Clinical chemistry - Indirect bilirubin

    To assess the indirect bilirubin as variables of safety and tolerability after administration of single dose of AZD9977 in combination with itraconazole.

    Time frame: From screening (Day -28) till follow-up visit (up to approximately 6 weeks)

  36. Number of participants with abnormal laboratory assessments: Serum Clinical chemistry - High-sensitivity troponin I ((hsTnI)

    To assess the High-sensitivity troponin I ((hsTnI) as variables of safety and tolerability after administration of single dose of AZD9977 in combination with itraconazole.

    Time frame: From screening (Day -28) till follow-up visit (up to approximately 6 weeks)

  37. Number of participants with abnormal laboratory assessments: Serum Clinical chemistry - N-terminal-pro-brain natriuretic peptide (NT-pro-BNP)

    To assess the N-terminal-pro-brain natriuretic peptide (NT-pro-BNP) as variables of safety and tolerability after administration of single dose of AZD9977 in combination with itraconazole.

    Time frame: From screening (Day -28) till follow-up visit (up to approximately 6 weeks)

  38. Number of participants with abnormal laboratory assessments: Clinical Urinalysis - Protein

    To assess the urine protein level as variables of safety and tolerability after administration of single dose of AZD9977 in combination with itraconazole. If urinalysis is positive for protein, a microscopy test will be performed to assess RBC, WBC, casts \[cellular, granular, hyaline\]).

    Time frame: From screening (Day -28) till follow-up visit (up to approximately 6 weeks)

  39. Number of participants with abnormal laboratory assessments: Clinical Urinalysis - Blood

    To assess the urine blood level as variables of safety and tolerability after administration of single dose of AZD9977 in combination with itraconazole. If urinalysis is positive for blood, a microscopy test will be performed to assess RBC, WBC, casts \[cellular, granular, hyaline\]).

    Time frame: From screening (Day -28) till follow-up visit (up to approximately 6 weeks)

  40. Number of participants with abnormal laboratory assessments: Clinical Urinalysis - Glucose

    To assess the urine glucose level as variables of safety and tolerability after administration of single dose of AZD9977 in combination with itraconazole.

    Time frame: From screening (Day -28) till follow-up visit (up to approximately 6 weeks)

07

Study locations

1 site
  • Research Site
    Baltimore, Maryland 21225, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2019 to primary completion in Apr 2019, 1 month.

Of 77 industry-sponsored phase 1 interventional studies under Heart Failure, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 16. This study's 1 month is below that.

Counting every sponsor, half of 131 studies reached it within 14 months; a quarter within 4 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 14, 2019
First posted
Feb 15, 2019
StartActual
Feb 22, 2019
Primary completionActual
Apr 1, 2019
CompletionActual
Apr 1, 2019
Last update
Apr 22, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 22, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03843060
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Feb 15, 2019
Start date
Feb 22, 2019
Primary completion
Apr 1, 2019
Completion
Apr 1, 2019
Last update
Apr 22, 2019

Study contacts

Ronald Goldwater
principal investigator · Dr.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: AZD9977 · Itraconazole

Start the discussion